Cookies

Like most websites The Translational Scientist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.

Respiratory

Disease Area

From MS to AMR

| Roisin McGuigan |

A drug used to treat MS could be repurposed to treat infections in cystic fibrosis patients

Disease Area

The Next (Air)Wave of Inhalables

| David Lewis |

For inhaler technology to evolve, questions about efficacy must be answered

Research Field

A Breath of Fresh Air?

| Roisin McGuigan |

Regulating the production of alpha-synuclein may be a new approach for treating Parkinson’s

Research Field

Womb with a View

| Roisin McGuigan |

Will premature infants soon be able to return to a uterine environment to finish their development?

Disease Area

Video of the Month

|

A biomedical device can give damaged lungs a breath of fresh air and make them donor-ready

Disease Area

Efficacy vs Effectiveness

| William Aryitey |

Tightly controlled efficacy studies can’t predict real-word effectiveness

Disease Area

In Good Company

| Bharathi Vennapusa |

What does it take to create a competitive companion diagnostic? Bharathi Vennapusa outlines her role in the development and approval of the ALK CDx – a fully-automated immunohistochemistry assay that identifies lung cancer patients who may be eligible for treatment with Pfizer’s Xalkori (crizotinib).

Disease Area

Engineering Better Health

|

Sitting Down With… Julian Solway MD, Walter L. Palmer Distinguished Service Professor - Medicine and Pediatrics, Director - Institute for Translational Medicine, Dean for Translational Medicine, University of Chicago, USA.

Disease Area

Making It (Im)personal

| Julian Solway |

Better understanding of human biology presents us with an opportunity to combat disease on two fronts – targeting individual variation on one hand and universal mechanisms on the other.


Register here

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts

Register